Sumitomo Pharma’s Xenleta Approved in China for Community-Acquired Pneumonia Treatment
Japan-based Sumitomo Pharma Co., Ltd announced that it has received market approval in China for...
Drug
BEBT-908 Receives Conditional NMPA Approval for Relapsed/Refractory DLBCL
Guangzhou BeBetter Medicine Technology Co., Ltd’s first-in-class HDAC/PI3Kα dual-targeted inhibitor BEBT-908 has received conditional approval...
CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received clinical trial approval...
Kanion Pharma and Space Peptides Submit IND for AI-Enabled CCR8 Peptide Inhibitor KYS2301
Chinese partners Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) and Space Peptides jointly announced the...
Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China
China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical...
Shanghai Henlius Biotech Earns GMP Certification for Prolia/Xgeva Biosimilar HLX14 and Perjeta Biosimilar HLX11
China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received Good Manufacturing Practice...
Dizal’s Sunvozertinib Receives FDA Accelerated Approval for EGFR Exon20ins NSCLC
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that the U.S. Food and Drug Administration...
Servier’s Voranigo Approved for IDH-Mutant Diffuse Glioma in Beijing
French firm Servier Pharmaceutical plc.’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2)...
Sichuan Biokin’s Iza-bren Meets Primary Endpoint in Phase III NPC Trial
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that its Phase III clinical study...
Genrix Bio Receives NMPA Clearance for GR1803 in Relapsed/Refractory Multiple Myeloma
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that it has received clinical trial...
Simcere Pharma’s Suvemcitug Approved by China’s NMPA for Platinum-Resistant Ovarian Cancer
China-based Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that it has received marketing approval...
China Resources Double-Crane Announces NMPA Clinical Approval for J002 Dry Eye Syndrome Treatment
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) announced that it has received clinical trial...
AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
Changchun GeneScience’s Firsekibart Receives NMPA Approval for Acute Gouty Arthritis
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received market approval for its...
CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT
China-based CANbridge Pharmaceuticals Inc., (HKG: 1228) announced that the first prescription of its Geruining (velaglucerase...
InnoCare Pharma Receives NMPA Clinical Approval for Innovative ADC B7-H3
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval...
Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical...
Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...
Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...
Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73
China-based Jacobio Pharma (HKG: 1167) announced the first patient dosing of a Phase I/IIa study...